Phase 3 Recruiting Network
This trial has two cohorts of patients with human epidermal growth factor receptor (HER)-2-positive breast cancer that has spread to other places in the body. All patients must be receiving trastuzumab-based treatment. Both cohorts are bei…
Sponsor: SWOG Cancer Research Network
NCT ID: NCT03418961
Sites in Ohio: - Cleveland Clinic Akron General — Akron, Ohio
- UHHS-Chagrin Highlands Medical Center — Beachwood, Ohio
- Indu and Raj Soin Medical Center — Beavercreek, Ohio
- Aultman Health Foundation — Canton, Ohio
- Dayton Physicians LLC-Miami Valley South — Centerville, Ohio
Phase 3 Recruiting Network
This phase III trial tests two hypotheses in patients with low-risk and average-risk medulloblastoma. Medulloblastoma is a type of cancer that occurs in the back of the brain. The term, risk, refers to the chance of the cancer coming back …
Sponsor: Children's Oncology Group
NCT ID: NCT05382338
Sites in Ohio: - Children's Hospital Medical Center of Akron — Akron, Ohio
- Cincinnati Children's Hospital Medical Center — Cincinnati, Ohio
- Rainbow Babies and Childrens Hospital — Cleveland, Ohio
- Nationwide Children's Hospital — Columbus, Ohio
- Dayton Children's Hospital — Dayton, Ohio
Phase 3 Recruiting Academic/Other
This phase III trial compares temporally-modulated pulsed radiation therapy versus standard radiation therapy in treating patients with newly diagnosed, IDH wildtype, MGMT-unmethylated glioblastoma. After completion of surgery, the standar…
Sponsor: NRG Oncology
NCT ID: NCT07452458
Sites in Ohio: - Case Western Reserve University — Cleveland, Ohio
Phase 3 Recruiting Industry
This is a 3-part study. The purpose of Part 1 of the study is to evaluate the efficacy, safety, and pharmacokinetic (PK) characteristics of safusidenib in participants with recurrent/progressive IDH1-mutant World Health Organization (WHO) …
Sponsor: Nuvation Bio Inc.
NCT ID: NCT05303519
Sites in Ohio: - Cleveland Clinic — Cleveland, Ohio
Phase 2, Phase 3 Recruiting Academic/Other
Glioblastoma (GBM) adaptive, global, innovative learning environment (GBM AGILE) is an international, seamless Phase II/III response adaptive randomization platform trial designed to evaluate multiple therapies in newly diagnosed (ND) and …
Sponsor: Global Coalition for Adaptive Research
NCT ID: NCT03970447
Sites in Ohio: - University Hospitals Cleveland Medical Center* — Cleveland, Ohio
- Cleveland Clinic — Cleveland, Ohio
- Ohio State University Cancer Center — Columbus, Ohio
Phase 3 Recruiting Industry
The brain is protected from any toxic or inflammatory molecule by the blood-brain barrier (BBB). This physical barrier is located at the level of the blood vessel walls. Because of these barrier properties, the blood vessels are also imper…
Sponsor: CarThera
NCT ID: NCT05902169
Sites in Ohio: - Neurological Institute Brain Tumor Centre Taussig Cancer Cente — Cleveland, Ohio
Phase 3 Recruiting Industry
This is a Phase 3 prospective, randomized, superiority, open-label, multi-site study. The overview of this study is as follows: * A Screening/Baseline Period of 21 days. During this time, patients will be randomized into a 1:2 allocation o…
Sponsor: GT Medical Technologies, Inc.
NCT ID: NCT07195591
Sites in Ohio: - The Ohio State University — Columbus, Ohio
Phase 2 Recruiting Network
This phase II trial compares the effect of encorafenib, binimetinib, and nivolumab versus ipilimumab and nivolumab in treating patients with BRAF- V600 mutant melanoma that has spread to the brain (brain metastases). Encorafenib and binime…
Sponsor: SWOG Cancer Research Network
NCT ID: NCT04511013
Sites in Ohio: - UHHS-Chagrin Highlands Medical Center — Beachwood, Ohio
- Indu and Raj Soin Medical Center — Beavercreek, Ohio
- Strecker Cancer Center-Belpre — Belpre, Ohio
- Saint Elizabeth Boardman Hospital — Boardman, Ohio
- Dayton Physicians LLC-Miami Valley South — Centerville, Ohio
Phase 2 Recruiting Network
This phase II trial studies the best approach to combine chemotherapy and radiation therapy (RT) based on the patient's response to induction chemotherapy in patients with non-germinomatous germ cell tumors (NGGCT) that have not spread to …
Sponsor: Children's Oncology Group
NCT ID: NCT04684368
Sites in Ohio: - Children's Hospital Medical Center of Akron — Akron, Ohio
- Cincinnati Children's Hospital Medical Center — Cincinnati, Ohio
- Rainbow Babies and Childrens Hospital — Cleveland, Ohio
- Cleveland Clinic Foundation — Cleveland, Ohio
- Nationwide Children's Hospital — Columbus, Ohio
Phase 1, Phase 2 Recruiting NIH
This phase I/II trial tests the safety, side effects, and best dose of selinexor given in combination with standard radiation therapy in treating children and young adults with newly diagnosed diffuse intrinsic pontine glioma (DIPG) or hig…
Sponsor: National Cancer Institute (NCI)
NCT ID: NCT05099003
Sites in Ohio: - Children's Hospital Medical Center of Akron — Akron, Ohio
- Cincinnati Children's Hospital Medical Center — Cincinnati, Ohio
- Rainbow Babies and Childrens Hospital — Cleveland, Ohio
- Nationwide Children's Hospital — Columbus, Ohio
- Dayton Children's Hospital — Dayton, Ohio
Phase 1, Phase 2 Recruiting NIH
This phase I/II trial tests the safety, side effects and best dose of selinexor given in combination with the usual chemotherapy (temozolomide) and compares the effect of this combination therapy versus the usual chemotherapy alone (temozo…
Sponsor: National Cancer Institute (NCI)
NCT ID: NCT05432804
Sites in Ohio: - University of Cincinnati Cancer Center-UC Medical Center — Cincinnati, Ohio
- Ohio State University Comprehensive Cancer Center — Columbus, Ohio
- University of Cincinnati Cancer Center-West Chester — West Chester, Ohio
Phase 2 Recruiting Industry
The objective of this Master Protocol is to evaluate the efficacy and safety of plixorafenib in participants with BRAF altered (BRAF V600E or BRAF fusions) locally advanced or metastatic solid tumors, or recurrent or progressive primary ce…
Sponsor: Fore Biotherapeutics
NCT ID: NCT05503797
Sites in Ohio: - Nationwide Children's Hospital — Colombus, Ohio
- The Ohio State University Comprehensive Cancer Center (OSUCCC) - The James Cancer Hospital and Solove Research Institute — Columbus, Ohio
- Taylor Cancer Research Center — Maumee, Ohio
- Toledo Clinic Cancer Center — Toledo, Ohio
Phase 1, Phase 2 Recruiting Academic/Other
BDTX-4933-101 is a first-in-human, open-label, Phase 1/2 dose escalation, dose optimization and expansion study designed to evaluate the safety and tolerability of S241656 as monotherapy and in combination with other anti-cancer therapies …
Sponsor: Institut de Recherches Internationales Servier
NCT ID: NCT05786924
Sites in Ohio: - Cleveland Clinic — Cleveland, Ohio
Phase 2 Recruiting Academic/Other
This phase II trial determines if the combination of ONC201 with different drugs is effective for treating participants with diffuse midline gliomas (DMGs). Despite years of research, little to no progress has been made to improve outcomes…
Sponsor: University of California, San Francisco
NCT ID: NCT05009992
Sites in Ohio: - Nationwide Children's Hospital — Columbus, Ohio
Phase 2 Recruiting Industry
The goal of this clinical trial is to learn if DOC1021 + pIFN alongside standard of care (SOC) will improve survival in adult patients newly diagnosed with glioblastoma (IDH-wt). It will also evaluate the safety of DOC1021 + pIFN. Research…
Sponsor: Diakonos Oncology Corporation
NCT ID: NCT06805305
Sites in Ohio: - The Ohio State University Comprehensive Cancer Center — Columbus, Ohio
Phase 2 Recruiting Industry
The objective of the study is to evaluate efficacy and safety of zanzalintinib in participants with recurrent or progressive meningioma refractory to standard therapies.
Sponsor: Exelixis
NCT ID: NCT07428616
Sites in Ohio: - The Ohio State University College of Medicine (OSUCOM) — Columbus, Ohio
Phase 1, Phase 2 Recruiting Industry
This is a first in human study of TNG456 alone and in combination with abemaciclib in patients with advanced or metastatic solid tumors known to have an MTAP loss. The first part of the study is an open-label, dose escalation and the secon…
Sponsor: Tango Therapeutics, Inc.
NCT ID: NCT06810544
Sites in Ohio: - Ohio State University Comprehensive Cancer Center — Columbus, Ohio
Phase 2 Recruiting Academic/Other
This study will address the question of whether targeting CMV antigens with PEP-CMV can serve as a novel immunotherapeutic approach in pediatric patients with newly-diagnosed high-grade glioma (HGG) or diffuse intrinsic pontine glioma (DIP…
Sponsor: Nationwide Children's Hospital
NCT ID: NCT05096481
Sites in Ohio: - Cincinnati Children's Hospital Medical Center — Cincinnati, Ohio
- Nationwide Children's Hospital — Columbus, Ohio
Phase 2 Recruiting Academic/Other
This is a Phase II open-label study to investigate the safety and efficacy of ACT001 in patients with DIPG and H3K27-altered HGG.
Sponsor: Nationwide Children's Hospital
NCT ID: NCT06838676
Sites in Ohio: - Cincinnati Children's Hospital — Cincinnati, Ohio
- Nationwide Children's Hospital — Columbus, Ohio
Phase 2 Recruiting Industry
The purpose of this research is to test an investigational device using ultrasound along with an investigational drug to see if it is useful in treating glioblastoma following standard of care therapy surgery and chemoradiation. This study…
Sponsor: Alpheus Medical, Inc.
NCT ID: NCT07225621
Sites in Ohio: - Ohio State University — Columbus, Ohio
Phase 2 Recruiting Industry
The goal of this study is to determine the efficacy of the study drug olutasidenib to treat newly diagnosed pediatric and young adult patients with a high-grade glioma (HGG) harboring an IDH1 mutation. The main question the study aims to a…
Sponsor: Rigel Pharmaceuticals
NCT ID: NCT06161974
Sites in Ohio: - Cincinnati Children's Hospital Medical Center — Cincinnati, Ohio
- Nationwide Children's Hospital — Columbus, Ohio
Phase 1, Phase 2 Recruiting Industry
This is a multi-site, global, open-label study that includes a phase 1b evaluation of elacestrant in combination with abemaciclib in women and men with brain metastases from estrogen receptor (ER)-positive, human epidermal growth factor re…
Sponsor: Stemline Therapeutics, Inc.
NCT ID: NCT05386108
Sites in Ohio: - Miami Valley Hospital South — Centerville, Ohio
Phase 2 Recruiting Industry
This study will evaluate BCB-276, an investigational B7-H3-targeted Chimeric Antigen Receptor (CAR) T cell therapy, in children and young adults with diffuse intrinsic pontine glioma (DIPG). DIPG is a rare and aggressive brain tumor with l…
Sponsor: BrainChild Bio, Inc
NCT ID: NCT07680439
Sites in Ohio: - Nationwide Children's Hospital — Columbus, Ohio
Phase 1, Phase 2 Recruiting Academic/Other
This study will evaluate the safety and efficacy of Lutathera (177Lu-DOTATATE) in patients with progressive or recurrent High-Grade Central Nervous System (CNS) tumors and meningiomas that demonstrate uptake on DOTATATE PET. The drug will …
Sponsor: Nationwide Children's Hospital
NCT ID: NCT05278208
Sites in Ohio: - Cincinnati Children's Hospital Medical Center — Cincinnati, Ohio
- Nationwide Children's Hospital — Columbus, Ohio
Phase 1, Phase 2 Recruiting Academic/Other
This study will consist of a Phase 1b and Phase 2 portion. The Phase 1b portion will enroll first followed by the Phase 2 portion. Each cycle of treatment = 28 days. Subjects will receive alectinib twice daily. Those in the Phase 1b portio…
Sponsor: Joshua Palmer
NCT ID: NCT05987644
Sites in Ohio: - Ohio State University Comprehensive Cancer Center — Columbus, Ohio